sponsored
PatientsVille.com Logo

PatientsVille

Erythema Medical Research Studies

Up-to-date List of Erythema Medical Research Studies

What Research is Being Done?

A clinical study involves research using human volunteers (also called participants) that is intended to add to medical knowledge. There are two main types of clinical studies: clinical trials (also called interventional studies) and observational studies. Following list includes both interventional and observational studies.

Latest Erythema Medical Research Studies

Rank Status Study
1 Recruiting Antibiotic Treatment of Multiple Erythema Migrans
Condition: Multiple Erythema Migrans
Interventions: Drug: ceftriaxone;   Drug: doxycycline;   Other: Erythema migrans patients treated with doxycycline
Outcome Measures: Objective sequelae and post-treatment subjective symptoms such as fatigue, malaise, arthralgias, headache, myalgias, paresthesias, dizziness, or irritability in patients treated for multiple Erythema migrans with ceftriaxone or doxycycline for 15 days.;   Comparison of subjective symptoms such as fatigue, malaise, arthralgias, headache, myalgias, paresthesias, or irritability between patients treated with antibiotic for multiple Erythema migrans and control subjects without a history of Lyme borreliosis.;   Objective sequelae and post-treatment subjective symptoms such as fatigue, malaise, arthralgias, headache, myalgias, paresthesias, dizziness, or irritability in patients with solitary versus multiple Erythema migrans after antibiotic treatment.
2 Recruiting Cytokines and Chemokines in Erythema Migrans
Condition: Erythema Migrans
Intervention: Drug: antibiotic treatment
Outcome Measures: inflammatory proteins in Erythema migrans patients;   gene polymorphisms in Erythema migrans patients
3 Unknown  Affect of Dose Rate on UVR Induced Skin Erythema
Condition: Erythema
Intervention: Device: exposure to UVB radiation
Outcome Measure: To examine the difference in Erythemal response as a function of dose rate, and to assess the total amount of energy that is theoretically transmitted through a sunscreen within the range of SPF 2-10
4 Recruiting Doxycycline in Therapy of Erythema Migrans
Condition: Lyme Borreliosis
Intervention: Drug: Doxycycline
Outcome Measures: Comparing of objective sequelae and post-treatment subjective symptoms in three groups of Erythema migrans patients treated with doxycycline: with no accompanying symptoms, with mild and with severe symptoms at the beginning.;   Comparison of subjective symptoms between Erythema migrans patients treated with doxycycline and control subjects without a history of Lyme borreliosis.
5 Recruiting Analysis of Lyme Disease Lesions
Conditions: Erythema Migrans Lesions;   Erythema Migrans
Intervention:
Outcome Measure:
6 Not yet recruiting Phase 3 Efficacy and Safety Study of CD07805/47 Topical Gel in Subjects With Persistent Facial Erythema
Condition: Erythema
Interventions: Drug: CD07805/47 Gel 0.5%;   Drug: CD07805/47 Gel Placebo
Outcome Measures: Composite success on both CEA (Clinician Erythema Assessment ) and PSA (Patient Self Assessment);   Composite improvement on both CEA (Clinician Erythema Assessment ) and PSA (Patient Self Assessment)
7 Not yet recruiting Safety and Efficacy of AGN-199201 in Patients With Persistent Erythema Associated With Rosacea
Conditions: Erythema;   Rosacea
Interventions: Drug: AGN-199201;   Drug: Vehicle to AGN-199201
Outcome Measures: Percentage of Participants with at Least a 2-Grade Decrease from Baseline on Both Clinician Erythema Assessment (CEA) and Subject Satisfaction Assessment (SSA) 5-point Scales;   Percentage of Participants with at Least a 2-Grade Decrease from Baseline on SSA Using a 5-Point Scale;   Change from Baseline in Rosacea Facial Redness as Measured by Digital Imaging Analysis (DIA);   Satisfaction Assessment for Rosacea Facial Redness Using a 5-Point Scale;   Symptom Assessment for Rosacea Facial Redness (Skin Sensation Domain Score) Using a 5-Point Scale;   Percentage of Participants with at Least a 1-Grade Decrease from Baseline on SSA Using a 5-Point Scale
8 Not yet recruiting Efficacy and Safety of AGN-199201 in Patients With Persistent Erythema Associated With Rosacea
Conditions: Erythema;   Rosacea
Interventions: Drug: AGN-199201;   Drug: Vehicle to AGN-199201
Outcome Measures: Percentage of Participants with at Least a 2-Grade Decrease from Baseline on Both Clinician Erythema Assessment (CEA) and Subject Satisfaction Assessment (SSA) 5-point Scales;   Percentage of Participants with at Least a 2-Grade Decrease from Baseline on SSA Using a 5-Point Scale;   Change from Baseline in Rosacea Facial Redness as Measured by Digital Imaging Analysis (DIA);   Satisfaction Assessment for Rosacea Facial Redness Using a 5-Point Scale;   Symptom Assessment for Rosacea Facial Redness (Skin Sensation Domain Score) Using a 5-Point Scale;   Percentage of Participants with at Least a 1-Grade Decrease from Baseline on SSA Using a 5-Point Scale
9 Not yet recruiting A Long-Term Safety and Efficacy Study of AGN-199201 in Patients With Persistent Erythema Associated With Rosacea
Conditions: Erythema;   Rosacea
Intervention: Drug: AGN-199201
Outcome Measures: Percentage of Participants with Treatment-Related Adverse Events;   Percentage of Participants with at Least a 2-Grade Decrease from Baseline on Both Clinician Erythema Assessment (CEA) and Subject Satisfaction Assessment (SSA) Using 5-Point Scales
10 Recruiting An Analysis of the Effect of Topical Cromolyn Sodium on Rosacea-associated Erythema
Condition: Papulopustular Rosacea
Interventions: Drug: Cromolyn Sodium;   Drug: Normal Saline
Outcome Measures: Facial Erythema;   Change in facial Erythema;   Matrix Metalloproteinase levels;   Change in matrix metalloproteinase levels
11 Unknown  Pulsed Dye Laser and Intense Pulsed Light (IPL) for the Treatment of Telangiectasia and Skin Redness
Conditions: Telangiectasis;   Erythema
Interventions: Device: Pulsed dye laser;   Device: Intense pulsed light
Outcome Measure:
12 Recruiting Culture Media for Borrelia Burgdorferi Sensu Lato
Condition: Erythema Migrans
Interventions: Other: MKP media;   Other: BSK-H media
Outcome Measure: detection of Borrelia burgdorferi sensu lato by microscopy in dark field (positive vs. negative)
13 Recruiting A Study of Nutritional Supplementation in Altering Ecchymosis, Erythema and Health Outcomes Associated With Aesthetic Procedures
Condition: Ecchymosis and Erythema Commonly Associated With Soft Tissue Filler Injections and Facial Ablative Laser Resurfacing Treatments.
Intervention: Dietary Supplement: Multizyme Cellular Vitality Cyruta Plus SHEP
Outcome Measures: Canfield Vectra Photography;   Heatherton & Polivy State Self-Esteem (HPSS) Scale, (SkinReplica) at Day 30 as compared to baseline (ablative laser group only, Global Aesthetic Improvement Scale (GAIS,
14 Unknown  Ciclosporin in the Management of New Erythema Nodosum Leprosum
Condition: Leprosy
Interventions: Drug: Ciclosporin;   Drug: prednisolone
Outcome Measures: time to relapse of ENL after initial control of symptoms;   time, in hours, to control initial episode of ENL relapse from time of starting anti-reactional medication;   time, in days, to ENL relapse from date of stopping anti-reactional medication
15 Unknown  Ciclosporin in the Management of Chronic or Recurrent Erythema Nodosum Leprosum
Condition: Leprosy
Interventions: Drug: prednisolone;   Drug: ciclosporin
Outcome Measure:
16 Recruiting Photodynamic Therapy for Papulopustular Rosacea
Conditions: Rosacea;   Papulopustular Rosacea
Interventions: Drug: Aminolevulinic acid topical solution 20%;   Device: Blu-U Light Therapy
Outcome Measures: Improvement of the inflammatory lesions (papules, pustules, nodules), Erythema, and telangiectasia of rosacea as assessed by the Investigator's Global Assessment (IGA);   Improvement of the inflammatory lesions (papules, pustules, nodules) of rosacea as assessed by the Inflammatory Lesion Investigator's Global Assessment (ILIGA);   Evaluate improvement of rosacea associated Erythema as assessed by the Clinical Erythema Assessment (CEA) scale;   Evaluate improvement of the inflammatory lesions (papules, pustules, nodules) of rosacea as measured by a difference in inflammatory lesion count;   Evaluate improvement of rosacea as assessed by the Patient Overall Assessment Scale
17 Unknown  Effect of Additional Clofazimine on Erythema Nodosum Leprosum (ENL) Reactions in Leprosy
Conditions: Borderline Lepromatous Leprosy;   Lepromatous Leprosy
Interventions: Drug: Clofazimine;   Drug: Vitamin capsule
Outcome Measures: Incidence of ENL reactions;   Severity of ENL reactions
18 Unknown  Montelukast in ENL Reaction
Conditions: Erythema Nodosum Leprosum;   Leprosy
Intervention: Drug: montelukast in treatment of ENL reaction
Outcome Measures: decrease in ENL score;   absence of new nerve function impairment;   incidence of adverse effects
19 Recruiting Observational Study of the Genetic Architecture of Neutrophil-Mediated Inflammatory Skin Diseases
Conditions: Other Specified Inflammatory Disorders of Skin or Subcutaneous Tissue;   Pyoderma Gangrenosum;   Erosive Pustular Dermatosis of the Scalp;   Sweet's Syndrome;   Behcet's Disease;   Bowel-associated Dermatosis-arthritis Syndrome;   Pustular Psoriasis;   Acute Generalized Exanthematous Pustulosis;   Keratoderma Blenorrhagicum;   Sneddon-Wilkinson Disease;   IgA Pemphigus;   Amicrobial Pustulosis of the Folds;   Infantile Acropustulosis;   Transient Neonatal Pustulosis;   Neutrophilic Eccrine Hidradenitis;   Rheumatoid Neutrophilic Dermatitis;   Neutrophilic Urticaria;   Still's Disease;   Erythema Marginatum;   Unclassified Periodic Fever Syndromes / Autoinflammatory Syndromes;   Dermatitis Herpetiformis;   Linear IgA Bullous Dermatosis;   Bullous Systemic Lupus Erythematosus;   Inflammatory Epidermolysis Bullosa Aquisita;   Neutrophilic Dermatosis of the Dorsal Hands (Pustular Vasculitis);   Small Vessel Vasculitis Including Urticarial Vasculitis;   Erythema Elevatum Diutinum;   Medium Vessel Vasculitis
Intervention: Procedure: Collection of biological samples
Outcome Measure: Enrichment of rare coding genetic variants
20 Recruiting Ultherapy® for the Treatment of Erythematotelangiectatic Rosacea
Conditions: Erythematotelangiectatic Rosacea;   Rosacea
Intervention: Device: Ulthera System Treatment
Outcome Measures: Clinician Erythema Assessment at 90 days post-treatment compared to baseline;   CEA scale at 180 days post-treatment compared to baseline.;   CEA scale at 365 days post-treatment compared to baseline.;   Patient Self-Assessment (PSA) of Erythema at 90 Days compared to baseline.;   Patient Self-Assessment (PSA) of Erythema at 180 Days compared to baseline.;   Patient Self-Assessment (PSA) of Erythema at 365 Days compared to baseline.;   Dermatology Life Quality Index (DLQI) Assessment at 90 Days post-treatment;   Dermatology Life Quality Index (DLQI) Assessment at 180 Days post-treatment;   Dermatology Life Quality Index (DLQI) Assessment at 365 Days post-treatment;   Colorimeter at 90 Days post-treatment;   Colorimeter at 180 Days post-treatment;   Colorimeter at 365 Days post-treatment

These studies may lead to new treatments and are adding insight into Erythema etiology and treatment.

A major focus of Erythema research is the development of new drugs and other treatment options. Studies seek to identify new drugs to treat various related disorders and to find safer, more effective doses for medications already being used. Other research is aimed at identifying receptors or drug targets.


Discuss Erythema